鹰瞳科技-B(02251)发布中期业绩期内溢利44.3万元同比扭亏为盈

智通财经

Aug 28

智通财经APP讯，鹰瞳科技-B(02251)发布截至2025年6月30日止六个月中期业绩，收入8371.3万元(人民币，下同);毛利6410.3万元，同比增加13.53%;期内溢利44.3万元，上年同期亏损8148.8万元，同比扭亏为盈。

公告称，报告期内，(i)集团的视网膜检测AI产品活跃服务网点从5,950个增加到7,180个，同比增长20.7%。鹰瞳医疗板块中等级医院和基层医疗UV数同比增长7.2%。通过SaMD和健康风险评估方案，集团在报告期内共检测了330万病例，同比增长11.4%。(ii)集团的近视防控AI产品使用次数达到281.2万，同比增长68.1%;其中，公司从2024年就开始构建基于PBM-LED近视光照治疗仪的经销服务体系和星级门店服务体系，截止到2025年上半年，该产品已覆盖全国20个省级行政区1,867个眼视光门店。(iii)集团的视觉训练AI产品训练次数达到了102.6万，同比增长11.6%。

报告期内，公司进一步拓展检测业务边界，成功开发并推出了基于无线传感技术(非接触式检测)和多模态AI算法技术的新一代生理抗压能力检测产品—“鹰瞳抗压能力检测仪”，该产品已完成产品定型与市场测试。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562205168"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562205168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562205168?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-28 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562205168","market":"us","top_or_hot":-1,"title":"鹰瞳科技-B(02251)发布中期业绩 期内溢利44.3万元 同比扭亏为盈","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02251\">鹰瞳科技-B</a>(02251)发布截至2025年6月30日止六个月中期业绩，收入8371.3万元(人民币，下同);毛利6410.3万元，同比增加13.53%;期内溢利44.3万元，上年同期亏损8148.8万元，同比扭亏为盈。</p><p>公告称，报告期内，(i)集团的视网膜检测AI产品活跃服务网点从5,950个增加到7,180个，同比增长20.7%。鹰瞳医疗板块中等级医院和基层医疗UV数同比增长7.2%。通过SaMD和健康风险评估方案，集团在报告期内共检测了330万病例，同比增长11.4%。(ii)集团的近视防控AI产品使用次数达到281.2万，同比增长68.1%;其中，公司从2024年就开始构建基于PBM-LED近视光照治疗仪的经销服务体系和星级门店服务体系，截止到2025年上半年，该产品已覆盖全国20个省级行政区1,867个眼视光门店。(iii)集团的视觉训练AI产品训练次数达到了102.6万，同比增长11.6%。</p><p>报告期内，公司进一步拓展检测业务边界，成功开发并推出了基于无线传感技术(非接触式检测)和多模态AI算法技术的新一代生理抗压能力检测产品—“鹰瞳抗压能力检测仪”，该产品已完成产品定型与市场测试。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>鹰瞳科技-B(02251)发布中期业绩 期内溢利44.3万元 同比扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n鹰瞳科技-B(02251)发布中期业绩 期内溢利44.3万元 同比扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-28 23:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1337983.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，鹰瞳科技-B(02251)发布截至2025年6月30日止六个月中期业绩，收入8371.3万元(人民币，下同);毛利6410.3万元，同比增加13.53%;期内溢利44.3万元，上年同期亏损8148.8万元，同比扭亏为盈。公告称，报告期内，(i)集团的视网膜检测AI产品活跃服务网点从5,950个增加到7,180个，同比增长20.7%。鹰瞳医疗板块中等级医院和基层医疗UV数同比增长...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1337983.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1189","symbol_name":"医疗保健技术","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1337983.html","article_id":"2562205168","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562205168","pubTimestamp":1756394680,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，鹰瞳科技-B 发布截至2025年6月30日止六个月中期业绩，收入8371.3万元;毛利6410.3万元，同比增加13.53%;期内溢利44.3万元，上年同期亏损8148.8万元，同比扭亏为盈。公告称，报告期内，集团的视网膜检测AI产品活跃服务网点从5,950个增加到7,180个，同比增长20.7%。鹰瞳医疗板块中等级医院和基层医疗UV数同比增长7.2%。通过SaMD和健康风险评估方案，集团在报告期内共检测了330万病例，同比增长11.4%。集团的视觉训练AI产品训练次数达到了102.6万，同比增长11.6%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1189":"医疗保健技术","02251":"鹰瞳科技-B"},"translate_title":"Eagle Eye Technology-B (02251) released interim results, with a profit of 443,000 yuan during the period, turning losses into profits year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02251":1},"content_text":"智通财经APP讯，鹰瞳科技-B(02251)发布截至2025年6月30日止六个月中期业绩，收入8371.3万元(人民币，下同);毛利6410.3万元，同比增加13.53%;期内溢利44.3万元，上年同期亏损8148.8万元，同比扭亏为盈。公告称，报告期内，(i)集团的视网膜检测AI产品活跃服务网点从5,950个增加到7,180个，同比增长20.7%。鹰瞳医疗板块中等级医院和基层医疗UV数同比增长7.2%。通过SaMD和健康风险评估方案，集团在报告期内共检测了330万病例，同比增长11.4%。(ii)集团的近视防控AI产品使用次数达到281.2万，同比增长68.1%;其中，公司从2024年就开始构建基于PBM-LED近视光照治疗仪的经销服务体系和星级门店服务体系，截止到2025年上半年，该产品已覆盖全国20个省级行政区1,867个眼视光门店。(iii)集团的视觉训练AI产品训练次数达到了102.6万，同比增长11.6%。报告期内，公司进一步拓展检测业务边界，成功开发并推出了基于无线传感技术(非接触式检测)和多模态AI算法技术的新一代生理抗压能力检测产品—“鹰瞳抗压能力检测仪”，该产品已完成产品定型与市场测试。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}